POLYMED1,749.00

Poly Medicure Ltd.

· Pharma & Health
₹ CrorePeersPFIZERRAINBOWONESOURCEKIMSJUBLPHARMAVIJAYAINDGNGRANULESMcap ₹17,728 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation63.981.4115.5
+ Finance Costs11.311.418.3
+ Interest Income-12.9-12.9-9.9
+ Dividend Income0.0-1.3-0.9
+ Fair Value (Gains) / Losses-20.9-37.7-52.8
+ Share-based Payments0.01.27.4
+ Unrealised FX (Gain) / Loss-1.8-1.4-11.7
+ Other Non-cash Items-0.2-4.43.6
Changes in Working Capital
+ Inventories-12.4-56.9-37.2
+ Trade Receivables — Current-36.7-84.8-99.3
+ Other Financial Assets — Current-5.64.03.0
+ Other Financial Assets — Non-current-1.7-0.8-1.4
+ Other Current Assets2.5-12.0-34.6
+ Other Non-current Assets0.10.2-3.1
+ Trade Payables — Current3.8-10.312.2
+ Other Financial Liabilities — Current13.58.5-9.9
+ Other Financial Liabilities — Non-current0.1-0.1-25.1
+ Other Current Liabilities-4.5-2.226.2
+ Other Non-current Liabilities0.00.010.0
+ Provisions — Current-0.00.12.5
+ Provisions — Non-current0.30.67.9
Cash from Operating Activities
Profit Before Tax (per I/S)341.7447.3421.8415.9
+ Total Adjustments (incl. Working Capital)-1.4-117.2-79.4
Cash from Operations (pre-tax)340.4330.1342.4
+ Income Taxes Paid74.389.0101.7
Cash from Operating Activities266.1241.1240.7
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)277.0325.0308.4
+ Disp of Fixed Assets1.90.72.6
+ Disp of Investment Property0.00.70.0
+ Acq of Other Long-term Assets15.0882.50.0
+ Disp of Other Long-term Assets35.50.0481.8
+ Acq of Subsidiaries / Businesses (net)0.00.0419.2
+ Dividends Received — Investing0.52.44.0
+ Interest Received — Investing13.212.513.8
Cash from Investing Activities-240.9-1,191.2-225.4
Cash from Financing Activities
+ Proceeds from Issue of Shares0.31,000.00.0
+ Proceeds from Exercise of Stock Options0.00.40.3
+ Proceeds from Borrowings0.010.474.6
+ Repayment of Borrowings-21.10.00.0
+ Payment of Lease Liabilities1.82.23.3
+ Interest Paid11.010.716.0
+ Dividends Paid28.730.335.4
+ Other Inflows / (Outflows) — Financing0.0-14.70.0
Cash from Financing Activities-20.2952.920.2
Net Changes in Cash (pre-FX)5.02.835.5
+ Effect of FX Rate Changes on Cash0.00.01.4
Net Changes in Cash5.02.836.8
Closing Cash12.18.7
Reference Items
EBITDA358.2452.8442.3461.4
EBITDA Margin %26.0427.1223.5923.10
Free Cash Flow (CFO − Capex)-10.9-83.9-67.7-67.7
Free Cash Flow to Equity-87.180.3
Free Cash Flow per Basic Share-1.08-8.28-6.68-6.68
Cash Flow to Net Income1.030.710.75
Cash Paid for Taxes74.389.0101.7
Cash Paid for Interest11.010.716.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.